PHASE II STUDY OF VIGIL® DNA ENGINEERED IMMUNOTHERAPY AS MAINTENANCE IN ADVANCED STAGE OVARIAN CANCER

Tuesday, July 26, 2016

Read the Story Here

Related Posts

Discover more posts like this.

Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies

Jul 24, 2024

Dr. Minal Barve

Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors

Jul 10, 2024

Dr. Minal Barve

Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL).

Jun 19, 2024

Dr. Reva Schneider
See All Posts